AR073651A1 - Formulaciones galenicas de compuestos organicos - Google Patents
Formulaciones galenicas de compuestos organicosInfo
- Publication number
- AR073651A1 AR073651A1 ARP090103629A ARP090103629A AR073651A1 AR 073651 A1 AR073651 A1 AR 073651A1 AR P090103629 A ARP090103629 A AR P090103629A AR P090103629 A ARP090103629 A AR P090103629A AR 073651 A1 AR073651 A1 AR 073651A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 7
- 239000007787 solid Substances 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 3
- 229960004699 valsartan Drugs 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000009490 roller compaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9959508P | 2008-09-24 | 2008-09-24 | |
| US16179909P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073651A1 true AR073651A1 (es) | 2010-11-24 |
Family
ID=41323516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103629A AR073651A1 (es) | 2008-09-24 | 2009-09-22 | Formulaciones galenicas de compuestos organicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110177166A1 (enExample) |
| EP (1) | EP2328562A1 (enExample) |
| JP (1) | JP2012503665A (enExample) |
| KR (1) | KR20110063684A (enExample) |
| CN (1) | CN102164584A (enExample) |
| AR (1) | AR073651A1 (enExample) |
| AU (1) | AU2009296718A1 (enExample) |
| BR (1) | BRPI0919077A2 (enExample) |
| CA (1) | CA2736259A1 (enExample) |
| CL (1) | CL2011000614A1 (enExample) |
| CO (1) | CO6351712A2 (enExample) |
| EC (1) | ECSP11010998A (enExample) |
| MA (1) | MA32722B1 (enExample) |
| MX (1) | MX2011003077A (enExample) |
| PE (1) | PE20110925A1 (enExample) |
| RU (1) | RU2011116122A (enExample) |
| TW (1) | TW201016210A (enExample) |
| WO (1) | WO2010036686A1 (enExample) |
| ZA (1) | ZA201101686B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR075880A1 (es) * | 2009-03-20 | 2011-05-04 | Novartis Ag | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. |
| EP2382967A1 (de) * | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
| TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| FR3055800B1 (fr) * | 2016-09-15 | 2020-06-26 | Unither Pharmaceuticals | Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules |
| CN114129569A (zh) * | 2020-09-04 | 2022-03-04 | 上海医药集团股份有限公司 | 一种含氮的饱和杂环化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| AR050615A1 (es) * | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
| PE20081157A1 (es) * | 2006-11-07 | 2008-09-26 | Novartis Ag | Forma cristalina de hemifumarato de alisquireno |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP2062874B1 (en) * | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
-
2009
- 2009-09-22 AR ARP090103629A patent/AR073651A1/es unknown
- 2009-09-23 AU AU2009296718A patent/AU2009296718A1/en not_active Abandoned
- 2009-09-23 TW TW098132133A patent/TW201016210A/zh unknown
- 2009-09-23 US US13/120,182 patent/US20110177166A1/en not_active Abandoned
- 2009-09-23 CN CN2009801373641A patent/CN102164584A/zh active Pending
- 2009-09-23 MX MX2011003077A patent/MX2011003077A/es not_active Application Discontinuation
- 2009-09-23 CA CA2736259A patent/CA2736259A1/en not_active Abandoned
- 2009-09-23 EP EP09792885A patent/EP2328562A1/en not_active Withdrawn
- 2009-09-23 PE PE2011000667A patent/PE20110925A1/es not_active Application Discontinuation
- 2009-09-23 KR KR1020117009209A patent/KR20110063684A/ko not_active Withdrawn
- 2009-09-23 RU RU2011116122/15A patent/RU2011116122A/ru not_active Application Discontinuation
- 2009-09-23 JP JP2011529177A patent/JP2012503665A/ja active Pending
- 2009-09-23 WO PCT/US2009/057993 patent/WO2010036686A1/en not_active Ceased
- 2009-09-23 BR BRPI0919077A patent/BRPI0919077A2/pt not_active IP Right Cessation
-
2011
- 2011-03-04 ZA ZA2011/01686A patent/ZA201101686B/en unknown
- 2011-03-23 CL CL2011000614A patent/CL2011000614A1/es unknown
- 2011-03-25 CO CO11036970A patent/CO6351712A2/es not_active Application Discontinuation
- 2011-04-20 MA MA33785A patent/MA32722B1/fr unknown
- 2011-04-21 EC EC2011010998A patent/ECSP11010998A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11010998A (es) | 2011-06-30 |
| ZA201101686B (en) | 2012-01-25 |
| TW201016210A (en) | 2010-05-01 |
| JP2012503665A (ja) | 2012-02-09 |
| MA32722B1 (fr) | 2011-10-02 |
| WO2010036686A1 (en) | 2010-04-01 |
| PE20110925A1 (es) | 2012-01-13 |
| KR20110063684A (ko) | 2011-06-13 |
| EP2328562A1 (en) | 2011-06-08 |
| US20110177166A1 (en) | 2011-07-21 |
| CA2736259A1 (en) | 2010-04-01 |
| BRPI0919077A2 (pt) | 2015-12-15 |
| MX2011003077A (es) | 2011-08-03 |
| CN102164584A (zh) | 2011-08-24 |
| CO6351712A2 (es) | 2011-12-20 |
| CL2011000614A1 (es) | 2011-11-04 |
| RU2011116122A (ru) | 2012-10-27 |
| AU2009296718A1 (en) | 2010-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
| PE20100559A1 (es) | Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla | |
| PE20141072A1 (es) | Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral | |
| JP2010174019A5 (enExample) | ||
| CO6470799A2 (es) | Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta | |
| PE20140099A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| JP2011509303A5 (enExample) | ||
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| Sardar et al. | Antiarrhythmic drug therapy for atrial fibrillation | |
| MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
| PA8629501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR077018A1 (es) | Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| PE20091885A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| JP2011527984A5 (enExample) | ||
| AR075880A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. | |
| ES2483366T3 (es) | Método y composición para el tratamiento de una afección mediada por el receptor de serotonina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |